Both BCC and SCC highly overexpress EGFR, and inhibitors for EGFR downstream intermediates such as BRAF (vemurafenib) and Src (dasatinib) are used in clinical settings [9]. This evidence concerns the gene EGFR and skin basal cell carcinoma.